Latest News & Updates

Breaking News

  • 1 minute ago

  • Simantini Singh Deo

"Neutrolis Appoints Former Pfizer Chief Scientific Officer Dr. Mikael Dolsten As Executive Director To Its Board To Advance Fast-Acting, Non-Immunosuppressive NET-Targeting Therapies "
Breaking News
Palisade Bio, Inc. Reports Rapid Clinical And Histologic Improvements With New Colon Tissue RNA-Seq Evidence Showing Targeted Activity Of PALI-2108 At The 21st Congress Of The European Crohn’s & Colitis Organization 2026

Simantini Singh Deo

Other trending news you may like to read

"Neutrolis Appoints Former Pfizer Chief Scientific Officer Dr. Mikael Dolsten As Executive Director To Its Board To Advance Fast-Acting, Non-Immunosuppressive NET-Targeting Therapies "

Neutrolis appoints former Pfizer CSO Dr. Mikael Dolsten to its Board as Executive Director.

Simantini Singh Deo

Pharma Now

Palisade Bio, Inc. Reports Rapid Clinical And Histologic Improvements With New Colon Tissue RNA-Seq Evidence Showing Targeted Activity Of PALI-2108 At The 21st Congress Of The European Crohn’s & Colitis Organization 2026

Palisade Bio reports rapid clinical and histologic gains with new RNA-seq data for PALI-2108 at ECCO 2026.

Simantini Singh Deo

Pharma Now

Tectonic Therapeutics Appoints Dr. François Nader As Chair And Independent Director Of Its Board Of Directors

Tectonic Therapeutics appoints Dr. François Nader as Chair and Independent Director, effective April 1, 2026.

Simantini Singh Deo

Pharma Now

Takeda’s Phase 3 KEPLER Trial Shows ENTYVIO Achieves Remission, Demonstrates Efficacy And Safety In Pediatric Ulcerative Colitis

Takeda’s Phase 3 KEPLER trial shows ENTYVIO achieves remission in pediatric ulcerative colitis.

Vaibhavi M.

Pharma Now